NHS patients denied new lung cancer drug after another NICE deadlockCertain untreated lung cancer patients on England’s NHS will have to make do with older drugs after NICE Share XNHS patients denied new lung cancer drug after another NICE deadlockhttps://pharmaphorum.com/news/nice-deadlock/
Janssen’s Darzalex approved in EU for newly-diagnosed multiple myelomaJanssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma. Share XJanssen’s Darzalex approved in EU for newly-diagnosed multiple myelomahttps://pharmaphorum.com/news/janssens-darzalex-approved-in-eu-for-multiple-myeloma/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCCNICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia Share XNICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCChttps://pharmaphorum.com/news/nice-rejects-astellas-xospata/
GSK’s CEO Walmsley aiming for six new approvals in 2020GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in Share XGSK’s CEO Walmsley aiming for six new approvals in 2020https://pharmaphorum.com/news/gsks-ceo-walmsley-aiming-for-six-new-approvals-in-2020/
Astellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapiesAstellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Share XAstellas to work with Adaptimmune to develop ‘off the shelf’ T-cell therapieshttps://pharmaphorum.com/news/astellas-to-work-with-adaptimmune-to-develop-off-the-shelf-t-cell-therapies/
Blueprint gets first approval as FDA backs stomach cancer drugUS biotech Blueprint Medicines has its first approved drug, after the FDA backed its oncology drug Ayvakit for Share XBlueprint gets first approval as FDA backs stomach cancer drughttps://pharmaphorum.com/news/blueprint-gets-first-approval-as-fda-backs-stomach-cancer-drug/
Life with multiple myelomaMultiple myeloma patient Bob Munro (pictured below) explains what it’s like to live with the rare blood cancer and Share XLife with multiple myelomahttps://pharmaphorum.com/partner-content/life-with-multiple-myeloma/
